As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients
Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI.